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Editorial 
The objective of this special issue was to highlight the chemical and biochemical factors that must 
be considered during the development of antibody-based radiopharmaceuticals for immuno-PET, 
immuno-SPECT and/or radioimmunotherapy (RIT). Notably, common subjects such as 
bioconjugation and modern site-specific labelling methods are not included since many excellent 
resources already exist. Rather, the emphasis is on the practicalities of working with radiolabelled 
antibodies with the aim of providing a brief, thought-provoking overview of the key concepts in 
radioimmunoconjugate design. 
Current trends in the pharmaceutical industry have witnessed wide-spread growth in area 
of biological products. Monoclonal antibodies and antibody-drug conjugates (ADCs) constitute 
more than 15% of the total number of New Molecular Entities that have received US-FDA 
approval since 2011. The radiochemistry community has also taken advantage of the growth in 
biologics, and nowadays, many new radiopharmaceuticals for diagnostic imaging and targeted 
radionuclide therapy are built upon antibody-based scaffolds. From the outside, the production of 
radiolabelled antibodies can appear deceptively simple – with the antibody in hand, the main work 
can be distilled to a two-step process involving bioconjugation of the protein with a metal binding 
chelate, followed by radiolabelling and purification. Standard protocols exist for both reaction 
steps. However, many potential pitfalls lie in wait for those inexperience in the subtleties of 
handling sensitive proteins.  
In their work entitled, ‘Preclinical optimization of antibody-based radiopharmaceuticals 
for cancer imaging and radionuclide therapy…’, Carter et al. provide a thorough account of many 
factors that must be incorporated into a comprehensive study design aimed at preclinical evaluation 
of radiolabelled antibodies. One aspect is the choice of radionuclide. Here, Aluicio Sarduy et al. 
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discuss the production and radioactive properties of several radiometals with potential use in 
immuno-PET. As most radiochemists know well from experience, the chemistry of the 
radionuclide plays a crucial role in the stability and pharmacokinetics of a radiotracer in vivo. My 
contribution, co-authored with Eszter Boros, looks at some of the chemical aspects of metal ion 
chelation in the synthesis of antibody-based radiotracers. Moving beyond the radiochemistry, 
Vivier et al. provide a fascinating and unique insight into the ‘…in vivo fate of 
radioimmunoconjugates for PET and SPECT’. High uptake and accumulation of radioactivity in 
organs like the liver, spleen and kidneys is sometimes attributed to instability of the radiotracer in 
vivo (for example, arising from the release of the metal ion from the chelate, antibody dimerisation 
or protein denaturation etc) but a more complete picture of the pharmacokinetics must also 
consider the natural uptake, metabolism and excretion pathways of antibodies themselves. 
Antibodies derived from natural selection methods are just one source of radioimmunoconjugates. 
Arguably a more advanced strategy to control pharmacokinetics is to ‘design’ new antibody-based 
constructs using protein engineering tools. Here, Tsai and Wu review current progress in the area 
of ‘…engineering antibodies for radionuclide delivery’. Finally, two articles review the current 
state of clinical research using antibody-based radiopharmaceuticals: Mark Bartholomä offers an 
up-to-date perspective on ‘Radioimmunotherapy of solid tumours’, while McKnight and Viola-
Villegas consider the rise in immunoPET using 89Zr-radiolabelled antibodies as companion 
diagnostics in clinical drug development.  
My hope is that the articles in this special issue will be of value to both experienced 
radiochemists working with antibodies, as well as students and those new to the field of 
radioimmunoconjugates.  
 
